Engrail Therapeutics Secures $157M in Series B Funding

Engrail Therapeutics, a precision neuroscience company based in San Diego, CA, has closed a $157M Series B financing round. The funding, led by F-Prime Capital, Forbion, and Norwest Venture Partners, will fuel the advancement of Engrail's pipeline in clinical development stages. Engrail, under the leadership of Vikram Sudarsan, Ph.D., aims to develop transformative therapies for patients with anxiety disorders, depression, PTSD, and rare neurodegenerative diseases. The company's board of directors has expanded to include Stacie Weninger, Ph.D., Jasper Bos, Ph.D., Tiba Aynechi, Ph.D., Niall O’Donnell, Ph.D., and Heath Lukatch, Ph.D. This funding marks a significant milestone for Engrail as it continues its mission to improve the lives of patients with unmet medical needs.